Description
Novatron Pharmacodynamics
Bronchodilator, in therapeutic doses has a marked stimulatory effect on beta2-adrenoreceptors of the bronchi, blood vessels and myometrium. It has practically no effect on the beta1-adrenoreceptors of the heart.
It has a pronounced bronchodilator effect, preventing or arresting bronchial spasm, reduces resistance in the airways, increases lung vital capacity. Increases mucociliary clearance (in chronic bronchitis up to 36%), stimulates mucus secretion, activates the functions of the atrial epithelium. May lead to a decrease in the number of beta-adrenoreceptors. It has a number of metabolic effects: decreases the concentration of potassium ions in plasma, affects glycogenolysis and insulin release, has hyperglycemic (especially in patients with bronchial asthma) and lipolytic effects, increases the risk of acidosis.
In the recommended therapeutic doses, it has no adverse effect on the cardiovascular system and does not cause an increase in blood pressure. To a lesser extent, compared to the drugs of this group, it has positive chrono- and inotropic effects. Causes dilation of the coronary arteries. After using inhaled forms, the action develops quickly, the beginning of the effect – after 5 minutes, the maximum effect – after 30-90 minutes (75% of the maximum effect is achieved within 5 minutes), the duration – 3-6 hours.
Indications
Prophylaxis and treatment of bronchospasm in bronchial asthma, symptomatic treatment of bronchoobstructive syndrome (including chronic bronchitis and pulmonary emphysema), reversible bronchial obstruction (prevention and treatment), including chronic obstructive pulmonary disease.
Contraindications
Hypersensitivity, children under 18 months of age.
The drug is not used in case of premature birth and in case of threatened abortion.
Caution
Tachyarrhythmia, myocarditis, cardiac defects, aortic stenosis, ischemic heart disease, severe chronic heart failure, arterial hypertension, thyrotoxicosis, pheochromocytoma, decompensated diabetes mellitus, glaucoma, pregnancy, breast-feeding period.
Use in pregnancy and during breast-feeding
It is not recommended to administer salbutamol during pregnancy and breast feeding unless the expected benefits to the mother exceed any possible risk to the fetus or child.
Dosage and administration method
- Novatron is used by inhalation with nebulizer inhalers (see section “How to use the drug” of these instructions).
- Adults, including elderly people and children over 18 months: Usual single dose is 2.5 mg when used 3-4 times a day by inhalation via nebulizer. If necessary, the dose may be increased to 5 mg 3-4 times a day.
- For treatment of severe airway obstruction in adult patients higher doses – up to 40 mg/day may be used under strict medical supervision in hospital conditions.
- Procedure for use of the drug:
1. Before using the drug, read the nebulizer manufacturer’s instructions.
2. Prepare nebulizer according to the manufacturer’s instructions.
3. Take the ampoule and shake it by holding the neck.
4. Squeeze the ampoule with your hand, making sure that there is no release of the drug, and with rotating movements turn and separate the valve.
5. Squeeze out the solution into the nebulizer reservoir.
6. Use the nebulizer according to the manufacturer’s instructions.
7. The solution left unused in the nebulizer chamber should be discarded immediately after each use.
8. Wash the nebulizer thoroughly. - Avoid getting the solution in the eyes when using the product.